Objective:

To review the evolution of adjuvant treatment strategies for renal cell carcinoma (RCC) and the impact of immune checkpoint inhibitors on patient outcomes.

Approach:

Key Findings:

• Surgical resection is the cornerstone of treatment for localized RCC, but many patients experience recurrence.
• Previous adjuvant strategies have largely failed to provide consistent survival benefits due to toxicity and poor tolerability.
• Adjuvant pembrolizumab has shown significant disease-free and overall survival benefits in selected high-risk patients.
• Not all immune checkpoint strategies yield benefits, highlighting the importance of patient selection.

Interpretation:

The review underscores a paradigm shift in RCC adjuvant therapy, moving towards personalized approaches that consider individual patient risk and biology.

Limitations:

• Historical failures of adjuvant therapies may bias perceptions of current treatment efficacy.
• The effectiveness of immune checkpoint inhibitors is not uniform across all patient populations.

Conclusion:

The landscape of adjuvant treatment for RCC is evolving, with immune checkpoint inhibitors offering new hope for high-risk patients, but further research is needed to refine treatment strategies.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.